Obesity Spotlight: Can BI Step Outside of Lilly’s Shadow?
In the second installment of FENIX’s Obesity Spotlight Series, FENIX has conducted a deep dive analysis of Boehringer Ingelheim’s strategy in the CVRM space. The analysis includes insights and thoughts on BI’s journey to commercialize survodutide and establish itself as an independent player in the obesity market beyond the BI/Lilly alliance. It should be reminded that BI is a privately traded company, and publicly available information is limited.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.